CA19-9 Detection Service

Creative Biolabs is a leading service provider that focuses on tumor-associated glycan detection. Based on our advanced platforms and extensive experience, now we provide the novel carbohydrate 19-9 antigen (CA19-9) detection service for the diagnostic of pancreatic cancer for our clients all over the world.

CA19-9 in Pancreatic Cancer

Pancreatic cancer is the 7^th leading cause of cancer mortality worldwide. Research shows that by 2030, pancreatic cancer (PC) will likely become the second leading cause of cancer-related deaths. In this case, it is urgent to determine reliable pancreatic cancer biomarkers for effective diagnosis and treatment against pancreatic cancer.

First discovered in 1979, CA19-9 is the most commonly used biomarker for the diagnostic and treatment of pancreatic cancer. Detection of serum CA19-9 presents a specificity of 95% and a sensitivity of 53%. The difference between preoperative and postoperative CA19-9 levels can be used as the basis for prognosis prediction. What’s more, the level of CA19-9 is related to tumor size, tumor stage, as well as tumor burden. In addition to being the most commonly utilized diagnostic biomarkers for pancreatic cancer, CA19-9 can be used for the prediction of tumor resectability, overall survival, survival, as well as therapy response.

However, there are known limitations for CA19-9 as a biomarker against pancreatic cancer. For example, false-positive results can be observed in benign pancreaticobiliary diseases like cholangitis, pancreatitis, or obstructive jaundice. The CA19-9 levels would also be interfered by hepatic and pancreatic cysts.

Fig 1. Therapeutic potential of CA19-9 for pancreatic cancer. (Luo, 2021)

Conditions Cause an Elevated CA19-9 Level

• Pancreatic cancer
• Pancreatitis
• Gallstones
• Liver disease
• Bile duct blockage
• Cystic fibrosis

Techniques for CA19-9 Detection in Pancreatic Cancer

Using an enzyme-linked immunosorbent assay (ELISA), the antigen CA19-9 concentration in human serum can be quantitatively determined. The assay system contains a monoclonal antibody against a distinct antigenic determinant on CA19-9 for solid-phase immobilization. The other HRP-conjugated CA19-9 monoclonal antibody is in the antibody-enzyme conjugate solution. The test sample would react sequentially with these two antibodies. After adding tetramethylbenzidine (TMB) reagent solution for incubation and staining, the absorbance representing the concentration of CA19-9 can be measured by spectrophotometry at 450 nm.

Creative Biolabs has been a long-term expert in the field of glycomics research. As a pioneer and the undisrupted global leader in tumor-associated glycan detection, we offer a variety of solutions to improve your productivity and streamline your research processes. If you are interested in our products or services, please do not hesitate to contact us for more detailed information.

Reference

1. Luo, G.; et al. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2021, 1875(2): 188409.

Related Services:

1. CA15-3 Detection Service
2. CA125 Detection Service
3. CA72-4 Detection Service
4. Prostate-specific Antigen (PSA) Detection Service
5. CEA Detection Service
6. Mucin Detection Service